Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kezar Life Sciences, Inc. - Common Stock
(NQ:
KZR
)
6.320
-0.020 (-0.32%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kezar Life Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
November 12, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
November 07, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans
↗
October 17, 2025
Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest.
Via
Benzinga
Looking Into Kezar Life Sciences's Recent Short Interest
↗
October 29, 2024
Via
Benzinga
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
↗
October 17, 2025
Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.
Via
Stocktwits
Topics
Workforce
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 17, 2025
Via
Benzinga
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
October 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 17, 2025
Via
Benzinga
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
↗
October 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 16, 2025
Via
Benzinga
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
October 16, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
August 28, 2025
From
Kezar Life Sciences
Via
Business Wire
Kezar Narrows Loss 37 Percent in Q2
↗
August 13, 2025
Via
The Motley Fool
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
↗
July 16, 2025
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review.
Via
Benzinga
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
July 15, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
↗
March 25, 2025
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.
Via
Benzinga
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 25, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
February 18, 2025
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
November 05, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
October 28, 2024
From
Kezar Life Sciences
Via
Business Wire
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
↗
October 17, 2024
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in...
Via
Benzinga
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
October 17, 2024
From
Kezar Life Sciences
Via
Business Wire
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
October 10, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 09, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
